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Background: Celiac disease is a widely prevalent enter-
opathy caused by intolerance to gliadin, one of the gluten
proteins. We developed two methods for the analysis of
gliadin levels. Both methods use ﬂow cytometry and rat
antibodies against a 16-residue peptide of gliadin. The
peptide is common to the -, -, -, and -gliadins.
Methods: In the one-site assay, the antigen (gliadin stan-
dard or food extract) was adsorbed on 3-m latex parti-
cles. Sensitized particles were then incubated, in this
order, with rat anti-gliadin peptide antibodies and anti-rat
immunoglobulin G antibodies labeled with ﬂuorescein
isothiocyanate. In the two-site assay, the antigen was
trapped on the latex particles by rat anti-gliadin antibodies
and then measured by the same antibodies labeled with
ﬂuorescein.
Results: Detection limits were 1 ng/ml for the one-site
assay and 10 pg/ml for the two-site assay. The two-site
assay displayed gliadin at concentrations above the limit
proposed by the Codex Alimentarius in 2 of 40 gluten-free
products.
Conclusion: There is a growing concern that gliadin,
even when present in gluten-free foods within the limit
ﬁxed by the Codex Alimentarius, over the long term may
become toxic to patients with celiac disease. The tech-
niques described in this study provide an opportunity to
further decrease the acceptable limit of gliadin in gluten-
free foods. © 2005 Wiley-Liss, Inc.
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People with celiac disease have an intolerance to a
33-residue peptide of wheat gliadin and to the related
proteins of rye and barley. Oats, rice, and maize do not
contain the peptide and are not toxic to the patient with
celiac disease (1–3). Celiac disease has a prevalence of 1 in
100 (2) to 1 in 300 (4) and is strongly associated with DQ2
or DQ8 HLA class II haplotypes (5). Only a small fraction
of the population carrying these risk haplotypes is af-
fected (2,6). Therefore, additional factors must contribute
to the development of the disease (2). The symptoms of
the disease disappear when patients follow a strict gluten-
free diet and reappear when gluten is reintroduced. As a
result, patients must follow a lifelong gluten-free diet.
The method more commonly used to measure gliadin is
enzyme-linked immunosorbent assay (7). Matrix-assisted
laser desorption/ionization time-of-ﬂy mass spectrometry
has also been proposed (8). The Codex Alimentarius has
established that gluten-free foods cannot contain more
than 10 ng of gliadin per milligram of food product (9).
This limit reﬂects the level of sensitivity of methods cur-
rently available for measuring gliadin. However, concern
has been expressed that the threshold ﬁxed by the codex
in the long term may not be entirely safe for the patient
with celiac disease (6,10,11). The two methods described
in this report provide a possibility to further decrease the
limit of gliadin allowed in gluten-free foods. Both methods
use ﬂow cytometry and rat antibodies against a 16-residue
peptide of gliadin. In the one-site assay, latex particles are
incubated with the unknown sample; the adsorbed gliadin
is then measured with rat antibodies to the gliadin peptide
and ﬂuorescein-labeled goat anti-rat immunoglobulin, in
that order. In the two-site assay, the same antiserum (rat
anti-gliadin peptide) is used to trap the gliadin on latex
particles and to label the trapped gliadin. Detection limits
are 1 ng/ml for the one-site assay and 10 pg/ml for the
two-site assay.
MATERIALS AND METHODS
Materials
Wheat, rye, barley, and oats cultivars included in this
study were provided by the Istituto Nazionale di Cereali-
coltura (Foggia, Italy); gluten-free foods were obtained
from the market.
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Gliadin Standards
Whole gliadin (1 mg; code G3375, Sigma-Aldrich Milan,
Italy) was dissolved in 1 ml of 70% ethanol, centrifuged at
104g (to remove undissolved material), analyzed for pro-
tein concentration by DC protein assay (Biorad, Milan,
Italy), diluted in 60% ethanol (100 to 1 ng/ml), and used as
standard. This gliadin (code G3375) was chosen because it
compares well to the European gliadin standard (7).
Sample Extraction
Flour samples were extracted with ethanol directly;
pasta, biscuit, and cake samples were ﬁrst homogenized
(2 min in a blade homogenizer). An aliquot of the sample
(1 mg) was incubated (3 h at room temperature) with 1 ml
of 60% ethanol, centrifuged at 104g, diluted in 60% etha-
nol (104 to 106), and analyzed by ﬂow cytometry. Arti-
ﬁcial mix experiments were carried out by adding 102 ng
to 1 pg of whole gliadin (Sigma-Aldrich) to 1 mg of gluten-
free ﬂour. Samples were then processed as described
above.
Peptide Synthesis and Conjugation
The gliadin peptide sequence, NMQVDPSGQVQW-
PQQQ, was assembled with solid-phase methodology on a
Pioneer 9050 synthesis system (PE Biosystem Italia,
Monza, Italy) on a 0.1-mmol scale using Fmoc chemistry
(12). The purity of the solid obtained (measured by ana-
lytical reverse-phase high-performance liquid chromatog-
raphy) was 85%. Determination of molecular weight
(1,871.75 atomic mass units) with matrix-assisted laser
desorption/ionization time-of-ﬂy analysis and Mass-Lynx
software were in agreement. This peptide was then con-
jugated to bovine serum albumin (BSA; Sigma-Aldrich)
using glutaraldehyde (Sigma-Aldrich) (13).
Antibody Production and Absorption
Antibodies were produced in Fischer 344 rats (Harlan,
Milan, Italy). Each animal received three intraperitoneal
injections at 2-week intervals. Each injection consisted of
200 g of conjugated peptide in 200 l of phosphate
buffered saline (pH 7.2; PBS) emulsiﬁed with an equal
volume of complete Freund’s adjuvant (ﬁrst injection) or
incomplete Freund’s adjuvant (second and third injec-
tions). The serum was collected 2 weeks after the last
injection. Antibodies to BSA and to the gliadin peptide
were removed by afﬁnity chromatography (see below).
Antibody Puriﬁcation
About 100 l of Protein G Dynabeads (Dynal Biotech,
Oslo, Norway) were washed with PBS and incubated (1 h
at room temperature on a rotating wheel) with 500 l of
BSA absorbed rat antibodies to the gliadin peptide
(RG16). The particles were kept at the bottom of the
tube with the help of a magnet and washed with PBS, and
bound antibodies were desorbed by incubation (2 min)
with 30 l of citrate buffer, pH 2 to 3. The pH was then
neutralized with 4 l of 1 M Tris buffer, pH 9, and the
antibody preparation was adjusted to a concentration of
500 to 700 g/ml.
Antibody Labeling
About 100 l of the RG16 antiserum were labeled
directly (without previous puriﬁcation) with ﬂuorescein
isothiocyanate (FITC) as described previously (14).
One-Site Assay
Latex particles (104, 2 104, 5 104, 105, and 2 105)
with a diameter of 3 m (code 17134, Polysciences, War-
rington, PA, USA) were incubated overnight with 1 ml of
gliadin standards dissolved in 60% ethanol or 1 ml of food
samples extracted with 60% ethanol. Particles were
washed with PBS, quenched with 2% milk blocking solu-
tion (Kirkegaard & Perry Laboratory, Gaithersburg, MD),
washed again, and incubated in succession with RG16
diluted 1:50 in PBS and anti-rat immunoglobulin G anti-
bodies labeled with FITC (GRFITC) diluted 1:600 in PBS.
GRFITC was obtained from Sigma-Aldrich. Samples were
analyzed on a FACScan ﬂow cytometer (Becton Dickinson
Immunocytometry Systems, San Jose, CA, USA). In the
analysis, a gate was set around the latex particles on the
basis of their forward and side scattering characteristics.
Standard markers were set by testing a negative control
(where RG16 antibodies were replaced with PBS). Data
were collected with logarithmic ampliﬁcation. Results are
presented as the mean channel of ﬂuorescence of the
treated sample subtracted from the mean channel of the
control. For each sample, data of 3,000 events were ana-
lyzed.
Two-Site Assay
About 4  105 latex beads (code 17134, Polysciences)
were incubated overnight at 4°C on a rotating wheel with
100 l of RG16 puriﬁed antibody. About 2  104 anti-
body-sensitized beads were then incubated with the anti-
gen (100 l of gliadin standards or food extracts for 2 h at
room temperature), washed with PBS, and incubated for
2 h with ﬂuorescein-labeled RG16 antibodies diluted
102 (50 l/tube), washed again with PBS, and analyzed as
described for the one-site assay.
Enzyme-Linked Immunosorbent Assay
The assay was carried out as described previously (15)
by using RG16 (diluted 1:50) and goat anti-ratHRP (Jack-
son Immunoresearch Laboratories, West Grove, PA, USA)
diluted 1:500.
Immunoblotting
After one-dimensional sodium dodecyl sulphate poly-
acrylamide gel electrophoresis (NuPAGE Novex 4–12%
Bis-Tris gels; Invitrogen, Carlsbad, CA), proteins were
transferred on a 0.2-m polyvinyl diﬂouride membrane
(Invitrogen), incubated with RG16 antibodies diluted
2  102, and visualized with goat anti-rat immunoglob-
ulin labeled with horse radish peroxidase diluted 103.
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Afﬁnity Chromatography
The ligand (BSA, the peptide used as immunogen, or
puriﬁed anti-gliadin antibodies) was coupled covalently to
amino polystyrene particles (code 19118, Polysciences) as
described by the manufacturer.
RESULTS AND DISCUSSION
Speciﬁcity of the Antiserum and Purity
of the Gliadin Standard
The antibodies used in this study were obtained by
immunizing rats with the 16-residue peptide NMQVDPS-
GQVQWPQQQ conjugated to BSA. Anti-BSA and anti-glia-
din peptide antibodies were removed from the antiserum
(RG16) by afﬁnity chromatography. Absorption with
BSA was carried out to remove the reactivity for the
carrier; absorption was done with the peptide to deter-
mine antibody speciﬁcity. After absorption with BSA and
with the peptide, the antiserum completely lost its ability
to react with wheat, barley, or rye extracts. These exper-
iments demonstrated that, properly absorbed, the reagent
was speciﬁc for the peptide used as an immunogen.
The reagent was then used to ascertain the purity of the
standard used in this study. When the gliadin standard
(100 ng/ml) was passed through a column containing
puriﬁed RG16 antibodies covalently bound to polysty-
rene beads, no protein was found in the efﬂuent.
Immunoblotting determined that the antiserum recog-
nizes the -, -, -, and -subunits (Fig. 1). The -, - and
-gliadins are structurally related, whereas the -gliadin is
structurally distinct (16). Detection of the four gliadin
fractions represents an important property of the anti-
serum. Previous studies implicated only the -gliadin in
disease activity (17), but subsequent studies demonstrated
that all gliadin fractions (including ) are enterotoxic for
patients with celiac disease (16,18–20). In addition, the
-gliadin, being stable during heat (7), could represent a
suitable target for gliadin detection in heat-processed
foods.
Validation of the One-Site Assay
To determine the optimal number of latex particles per
tube, different numbers of particles (104 to 2  105) were
incubated with a constant volume of gliadin standards.
Gliadin-sensitized beads were then incubated, in this or-
der, with different dilutions of the primary (RG16) and
secondary (GRFITC) antibodies. The 100-ng/ml (Fig. 2)
and 1-ng/ml (data not shown) gliadin standards displayed
a higher mean channel (higher ﬂuorescence) when 2 
104 particles/tube were used, and the primary and sec-
ondary antibodies were diluted 2  102 and 2  103,
respectively. The ﬂuorescence intensity of the standards
was further improved by ﬁne adjustments of GRFITC
dilution to 1.5  103. Under these conditions, the detec-
tion limit of the assay (minimum concentration of gliadin
that produced a signal clearly distinct from blank) was
1 ng/ml for wheat (Fig. 3), barley, and rye samples indif-
ferently (data not shown). The intra-assay coefﬁcient of
variation was 1.8% to 3.2% (n  30), and the interassay
coefﬁcient of variation was 2.2% to 5.4% (n  10).
To establish which percentage of gliadin in the sample
was detected by the method, known amounts of gliadin
were added to 1 mg of gluten-free ﬂour. The gliadin
detected was at least 87% of the gliadin added to the
gluten-free ﬂour (Fig. 4). In these artiﬁcial mix experi-
ments, 1 ng of gliadin added to 1 mg of gluten-free ﬂour
(i.e., 1 ppm) was easily detected (Fig. 5).
Two-Site Assay
A two-site (or sandwich) assay seemed the logical de-
velopment of the one-site assay just described. It was
assumed that latex beads sensitized with RG16 antibod-
ies would trap the gliadin more efﬁciently than would
nonsensitized beads. In this case, the assay would detect
gliadin at a concentration lower than 1 ng/ml (detection
FIG. 2. One site-assay carried out with a variable number of latex beads
per tube (104, 2  104, 5  104, 105, or 2  105). The amount of gliadin
per tube was kept constant (100 ng/ml). The experiments described in
the text were carried out with 2  104 particles/tube.
FIG. 1. Immunoblotting of -, -, -, and -gliadins. Lanes 1 and 3:
gliadin standard (Sigma-Aldrich) at 1 and 10 mg/ml, respectively. Lanes 2,
4, 6, 8: four different gluten-free food samples. Lanes 5 and 7: ﬂour
samples at 10 and 20 mg/ml extracted with 60% ethanol. M, marker
(SeeBlue Plus2 Prestained Standard, Invitrogen). The primary antibody
was RG16 and the secondary antibody was goat anti-mouse immuno-
globulin G labeled with horse radish peroxidase.
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limit of the one-site assay). Moreover, gliadin, in particular
the -fraction (21), contains repetitive sequences (16). If
the antiserum detected a recurrent epitope on the gliadin
molecule, then the same reagent (RG16) could work as
a binding antibody (immobilized on the latex beads) and a
detector antibody (in a ﬂuorescein-labeled form). The as-
say developed accordingly and displayed the capacity to
detect gliadin at 10 pg/ml (Fig. 6). The intra-assay coefﬁ-
cient of variation was 2.3% to 7.4% (n  15), and the
interassay coefﬁcient of variation was 3.4% to 9.2%
(n  5).
In artiﬁcial mix experiments, the assay detected 85% to
90% of the gliadin added to the ﬂour (data not shown).
This proteomic two-site assay performs better than the
genomic real-time polymerase chain reaction assay re-
cently described, which detects 160 pg/ml of gliadin (22).
In this technique, the gliadin in the sample is detected by
the monoclonal antibody R5 directly conjugated with an
oligonucleotide probe. The probe, coupled with a re-
porter and a quenching dye, is degraded by the 5	-3	
exonuclease activity of DNA polymerase and the reporter
dye freed from the quenching dye. Thus the ﬂuorescence
intensity is proportional to the amount of polymerase
chain reaction product formed.
Food Analysis by the One-Site Assay
The next objective was to determine whether gliadin
was present in ﬂour and gluten-free food samples above
the limit imposed by the Codex Alimentarius. This limit,
10 ng of gliadin per milligram of food product, was out-
FIG. 3. Standard curve for gliadin quantiﬁcation by the one-site assay. The low (1–10 ng/ml; A) and high (25–100 ng/ml; B) ranges are shown separately
to visualize better the lowest (1 ng/ml) point of the curve. Each point is the average of 10 independent assays. Results are presented as ﬂuorescence
intensity of the activity tubes minus the ﬂuorescence intensity of the control tubes (where RG16 was omitted).
FIG. 4. Recovery of added gliadin in an artiﬁcial mix. Gliadin standards
at 1, 5, 10, 25, 50, 75, and 100 ng/ml (white bars) and percentage of
gliadin recovered from artiﬁcial mixes containing 1, 5, 10, 25, 50, 75, and
100 ppm (gray bars). Recovered gliadin was at least 87%. Error bars
represent the standard deviation of 30 determinations.
FIG. 5. Gliadin recovery in artiﬁcial mix of gliadin with gluten-free ﬂour.
One part per million of product (1 ppm) was easily detected by the
one-site assay. C, control (no gliadin added); 1, 10, 50, 100, ﬂow cyto-
metric proﬁles of 1 mg of gluten-free ﬂour mixed with 1, 10, 50, and
100 ng of gliadin and then extracted with 1 ml of 60% ethanol. Numerical
range, 100 to 104. Type of scale, logarithmic.
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side the range of the two-site assay. For this reason, the
less sensitive one-site assay was used.
Gliadin was detected at a concentration higher than
10 ng/ml in 6 of 45 gluten-free food samples and was
totally absent only in seven. The analysis was extended to
15 products in which gliadin was expected to be absent
(processed cheese products, fruit juice, sausage, morta-
della, and salami). Surprisingly, two of these products
showed a gliadin concentration above 10 ng/ml and the
remaining 13 showed a concentration of 1.5 to 8.3 ng/ml.
The assay was used to detect gliadin in ﬂour and food
samples after treatment of extracts at 120°C for 30 min.
The thermal process decreased gliadin concentration by
only 10% to 15%. Because heat treatment during food
processing does not affect gliadin toxicity (23), the capac-
ity of the assay to identify heat-treated gliadin is signiﬁ-
cant.
Relative Importance of Variables
Involved in Assays
RG16 antibodies in a standard enzyme-linked immu-
nosorbent assay format (Fig. 7) displayed a detection limit
of 10 ng/ml (vs. the 1-ng/ml detection limit of the corre-
sponding one-site assay). In our experience, the use of
beads is best exploited in association with the ﬂow cy-
tometer. Therefore, these two variables were not analyzed
individually. Depending on the analytical sensitivity re-
quired, the researcher may decide to use the one-site assay
(with a detection limit of 1 ng/ml) or the two-site assay
(with a detection limit of 10 pg/ml). Thus the main vari-
able responsible for the improvements displayed by the
methods described in this report over the current ones is
the combined use of beads and ﬂow cytometry.
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